Phaseline

Companies › Guangzhou Xiling Biotechnology

Guangzhou Xiling Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CEL001 injection
NK cell preparation
–Phase 1Advanced Solid Tumors (Phase 1)Jun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07259889CEL001 injectionPhase 1Advanced Solid Tumors (Phase 1)OncologyJun 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.